CervoMed Inc.
CervoMed Inc. (CRVO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
crvo · stock forecast · 7 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$9.00
Consensus
$9.00
+209.3% upside
Low
$9.00
Median: $9 · Last Close: $2.91
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.79 | ↓ 3.99% |
1-day model range: $2.74–$2.85. Peak: $2.85 (-3.99%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -50.0% |
| 2028 | — | -62.5% |
| 2029 | — | -67.2% |
| 2030 | — | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · CRVO · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-04-23 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-04-22 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-04-08 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-19 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-18 | Roth Capital | Maintains | Buy→Buy |
| 2026-03-18 | Chardan Capital | Maintains | Buy→Buy |
| 2026-03-16 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-05 | Chardan Capital | Maintains | Buy→Buy |
| 2026-03-04 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-02-18 | D. Boral Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on CervoMed Inc. (CRVO) stock. Of the recent 46 rating actions, 4 were upgrades and 4 were downgrades. 7 analysts currently cover CRVO.
Analyst Recommendation Trends
CRVO analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 3 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 81.7% YoY
Revenue Next Year
$1M
↑ 264.6% YoY
EPS This Year
$-2.70
EPS Next Year
$-2.46
↓ 8.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast CRVO EPS of $-2.70 for the current fiscal year, based on estimates from 5 analysts. The CRVO revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CRVO stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CRVO price target is $9.00 (+209.3% upside), with an analyst consensus of Buy.
The CRVO short-term stock prediction for tomorrow is $2.79 (-3.99%). The CRVO stock prediction for 2030 projects a range of $1–$1.
CervoMed Inc. trades on NASDAQ under the ticker CRVO. The CRVO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
CRVO forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month CRVO price target is $9.00, with a high forecast of $9.00 and a low of $9.00. The median price target is shown in the chart above when available. This implies +209.3% potential upside from the current price of $2.91.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.